Moxonidin Heumann (Moxonidine)

Moxonidine selectively activates central imidazoline I1 receptors, reducing sympathetic nervous system activity. This leads to decreased peripheral vascular resistance and a modest reduction in heart rate, together producing a lowering of arterial blood pressure.

The dosage of Moxonidin Heumann is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function and concomitant therapies. Only a qualified health professional should determine the appropriate dose.

The safety of moxonidine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified health‑care provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Moxonidine differs from beta‑blockers, ACE inhibitors and calcium‑channel blockers by targeting central imidazoline I1 receptors rather than peripheral vascular or renin‑angiotensin pathways. This mechanism may result in fewer metabolic side effects, but individual response varies and therapy should be tailored to each patient.

Moxonidin Heumann should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

The product is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, bradycardia, allergic reactions such as rash or swelling, and rare hepatic dysfunction. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or signs of liver injury.

Moxonidin Heumann is contraindicated in patients with known hypersensitivity to moxonidine or any excipients, and it should be used with caution in individuals with severe renal impairment, uncontrolled heart failure, or those taking other potent antihypertensives that may cause additive blood‑pressure lowering.